Rhinitis 2017 Update - BSACI

Rhinitis 2017 Update

Clinical & Experimental Allergy. Volume 47, Issue 7, July 2017, Pages: 856-889

To access the full version of the guideline, please click here


This is an updated guideline for the diagnosis and management of allergic and nonallergic rhinitis, first published in 2007. It was produced by the Standards of Care Committee of the British Society of Allergy and Clinical Immunology, using accredited methods. Allergic rhinitis is common and affects 10–15% of children and 26% of adults in the UK, it affects the quality of life, school and work attendance, and is a risk factor for the development of asthma. Allergic rhinitis is diagnosed by history and examination, supported by specific allergy tests. Topical nasal corticosteroids are the treatment of choice for moderate to severe disease. Combination therapy with intranasal corticosteroid plus intranasal antihistamine is more effective than either alone and provides second-line treatment for those with rhinitis poorly controlled on monotherapy. Immunotherapy is highly effective when the specific allergen is the responsible driver for the symptoms. Treatment of rhinitis is associated with benefits for asthma. Non-allergic rhinitis also is a risk factor for the development of asthma and may be eosinophilic and steroid-responsive or neurogenic and noninflammatory. Non-allergic rhinitis may be a presenting complaint for systemic disorders such as granulomatous or eosinophilic polyangiitis, and sarcoidosis. Infective rhinitis can be caused by viruses, and less commonly by bacteria, fungi and protozoa.


allergen, allergic, allergy, antihistamine, anti-leukotriene, aspirin, asthma, BSACI, cat allergen, child, corticosteroid, cromoglycate, decongestant, guideline, house dust mite, idiopathic rhinitis, IgE, immunotherapy, ipratropium bromide, lactation, non-allergic, non-infectious rhinitis, nitric oxide, non-allergic, non-infectious rhinitis, occupational, pregnancy, quality of life, rhinitis, rhinitis control, skin prick test, Standards of Care Committee, subcutaneous immunotherapy, sublingual immunotherapy, surgery


G. K. Scadding, H. H. Kariyawasam, G. Scadding, R. Mirakian, R. J. Buckley, T. Dixon, S. R. Durham, S. Farooque, N. Jones, S. Leech, S. M. Nasser, R. Powell, G. Roberts, G. Rotiroti, A. Simpson, H. Smith, A. T. Clark


BSACI guidance for prescribing Palforzia® Peanut Oral Immunotherapy published

Read more